Formulary
Bictegravir with emtricitabine and tenofovir alafenamide: Indications, Dosing, Side Effects and Interactions
Bictegravir with emtricitabine and tenofovir alafenamide clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Bictegravir with emtricitabine and tenofovir alafenamide: Indications, Dosing, Side Effects and Interactions
Bictegravir with emtricitabine and tenofovir alafenamide clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**HIV-1 infection [doses**
- **Adult** (By Mouth): for 50/200/25 mg tablets] (initiated by a specialist) 1 tablet once daily.
**HIV-1 infection [doses for 30/120/15 mg tablets] (initiated by a specialist) for bictegravir with emtricitabine and tenofovir alafenamide**
- **Child 2-17 years (body-weight 14-24 kg)** (By mouth): 1 tablet once daily.
**HIV-1 infection [doses for 50/200/25 mg tablets] (initiated by a specialist) for bictegravir with emtricitabine and tenofovir alafenamide**
- **Child 2-17 years (body-weight 25 kg and above)** (By mouth): 1 tablet once daily.
Side effects
For bictegravir with emtricitabine and tenofovir alafenamide Common or very common Depression; diarrhoea; dizziness; fatigue; headache; nausea; sleep disorders Uncommon Anaemia; angioedema; anxiety; arthralgia; flatulence; gastrointestinal discomfort; hyperbilirubinaemia; skin reactions; suicidal behaviours; vomiting Rare or very rare Stevens-Johnson syndrome Frequency not known Osteonecrosis
Pregnancy
For bictegravir with emtricitabine and tenofovir alafenamide Use only if potential benefit outweighs risk (limited information on bictegravir). M
Hepatic impairment
For bictegravir with emtricitabine and tenofovir alafenamide Avoid in severe impairment (no information available). M
Renal impairment
For bictegravir with emtricitabine and tenofovir alafenamide Avoid if creatinine clearance is less than 30 mL/minute (limited information available). M See Prescribing in renal impairment . Caution in patients weighing <35kg with any degree of renal impairment (no information available). M
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Bictegravir with emtricitabine and tenofovir alafenamide in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

